Management of Hypertensive Nephropathy
For patients with hypertensive nephropathy, target blood pressure should be <130/80 mmHg using renin-angiotensin system (RAS) blockers as first-line therapy, combined with additional agents as needed to achieve this goal. 1
Blood Pressure Targets
- Target BP <130/80 mmHg for all patients with chronic kidney disease (CKD) and hypertension 2, 3, 1
- For patients with proteinuria >1 g/day, consider even more aggressive targets approaching <125/75 mmHg to maximally slow progression 2, 4
- The 2024 ESC guidelines recommend targeting systolic BP to 120-129 mmHg when tolerated in most patients, though this may not generalize to all CKD populations 5
- The KDIGO 2021 guidelines suggest targeting SBP <120 mmHg when tolerated using standardized office BP measurement, though clinicians can offer less intensive therapy in patients with very limited life expectancy or symptomatic orthostatic hypotension 1
Important caveat: Achieving BP <130/80 mmHg typically requires three or more antihypertensive agents in most patients with CKD 2, 6, 7
First-Line Pharmacotherapy
ACE Inhibitors or ARBs as Foundation
- ACE inhibitors or ARBs are recommended as initial therapy for all patients with hypertensive nephropathy, particularly those with albuminuria 3, 8, 1
- For patients with severely increased albuminuria (A3) without diabetes, starting RAS inhibitors is strongly recommended 1
- For patients with moderately-to-severely increased albuminuria (A2-A3) with diabetes, RAS inhibitors are strongly recommended 1
- Use the highest approved dose tolerated to achieve maximum renoprotective benefit 1
Monitoring After RAS Inhibitor Initiation
- Check serum creatinine and potassium within 2-4 weeks of starting or increasing RAS inhibitor dose 1
- Continue therapy unless creatinine rises >30% within 4 weeks of initiation 1
- Hyperkalemia can often be managed with potassium-lowering measures rather than discontinuing the RAS inhibitor 1
Critical warning: Never combine ACE inhibitor + ARB + direct renin inhibitor - this triple combination is contraindicated due to increased serious adverse events without additional benefit 6, 1
Combination Therapy Strategy
Rational Drug Combinations
- The most effective combination for achieving BP goals consists of: RAS blocker + calcium channel blocker + thiazide/thiazide-like diuretic 2, 6, 9
- Dihydropyridine calcium channel blockers are preferred over non-dihydropyridines for combination therapy 10, 3
- Loop diuretics may be required instead of thiazides when eGFR is significantly reduced 2
Agents to Add for Resistant Hypertension
- Spironolactone for resistant hypertension when eGFR ≥30 mL/min/1.73 m² (monitor potassium closely) 1, 11
- Chlorthalidone for resistant hypertension when eGFR <30 mL/min/1.73 m² 11
- Beta-blockers can be added, particularly in patients with high sympathetic drive (elevated pulse rate) 7
Combinations to Avoid
- Beta-blocker + diuretic combination should be avoided as initial therapy due to increased diabetes risk 6
- Alpha-blockers are not recommended as first-line agents 10
Additional Therapeutic Considerations
Proteinuria Reduction
- Reducing proteinuria is a key therapeutic goal beyond BP control, as it independently predicts slowing of CKD progression 9
- RAS blockers provide antiproteinuric effects that contribute to renoprotection beyond BP lowering alone 2, 8
Newer Agents
- SGLT2 inhibitors should be considered for patients with CKD and eGFR ≥20 mL/min/1.73 m² 11
- Finerenone (non-steroidal mineralocorticoid receptor antagonist) for patients with CKD, type 2 diabetes, albuminuria, eGFR ≥25 mL/min/1.73 m², and potassium <5.0 mmol/L 11
Lifestyle Modifications
- Dietary sodium restriction to <5 g sodium chloride per day (<2 g sodium) 1
- Moderate-intensity physical activity for ≥150 minutes per week when compatible with cardiovascular tolerance 1
- Protein restriction to 0.8 g/kg/day once overt nephropathy develops 8
Important exception: Sodium restriction is not appropriate for patients with salt-wasting nephropathy 1
When to Refer to Nephrology
- Proteinuria >500 mg/24 hours (or ACR ≥30 mg/mmol) with hematuria 12
- eGFR <60 mL/min/1.73 m² or difficulties managing hypertension or hyperkalemia 8
- Creatinine rise >30% after RAS inhibitor initiation 1
- Uncontrolled hyperkalemia despite medical management 1
Common Pitfalls to Avoid
- Undertreatment: Most patients require 3+ agents; don't hesitate to escalate therapy 2, 7
- Premature discontinuation of RAS inhibitors: Small creatinine rises (<30%) are acceptable and expected 1
- Using non-standardized BP measurements: The intensive targets (SBP <120 mmHg) are potentially hazardous if applied to non-standardized measurements 1
- Inadequate monitoring: Failure to check potassium and creatinine 2-4 weeks after RAS inhibitor changes 1